Preliminary First Quarter 2019 Results The Company expects worldwide sales from continuing operations for the first quarter 2019 to be approximately $251 million, flat on a reported basis and an increase of 4.0 percent on a constant-currency basis compared to the first quarter of 2018. Neuromodulation sales are anticipated to […]
Financial
BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call
FRANKLIN LAKES, N.J., April 4, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2019 earnings conference call on Thursday, May 9, 2019, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter’s earnings earlier that morning. The […]
AtriCure to Announce First Quarter 2019 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, […]
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
Email Print Friendly Share April 04, 2019 06:00 ET | Source: InspireMD, Inc. TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously […]
Milestone Pharmaceuticals Appoints Michael Tomsicek to Board of Directors
MONTREAL and CHARLOTTE, N.C., April 4, 2019 /PRNewswire/ — Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, today announced the appointment of Michael Tomsicek to its Board of Directors. Mr. Tomsicek is currently the Chief Financial Officer of CRISPR Therapeutics, a biopharmaceutical company focused on developing gene-based medicines. In addition […]
Silk Road Medical Announces Pricing of Initial Public Offering
SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk […]
Tioga Medical, A Shifamed Portfolio Company, Closes $15M In Series A Financing
CAMPBELL, Calif., April 4, 2019 /PRNewswire/ — Tioga Medical, a newly formed Shifamed portfolio company, announced today the closing of its Series A preferred stock financing, raising a total of $15M. Tioga Medical was founded to provide physicians and patients with an elegant transcatheter valve replacement experience that is procedurally simpler and less invasive […]
InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today announced the appointment of Daniel G. Welch as executive chairman of the company’s board of directors, effective March 7, 2019. Mr. Welch possesses more than 30 […]
SynCardia Announces Promotion of Don Webber to CEO & Appointment of Peter Spadaro as President and CCO
TUCSON, Arizona, April 3, 2019 /PRNewswire/ — SynCardia Systems, LLC, manufacturer of the world’s only clinically-proven and commercially approved total artificial heart, is pleased to announce that Don Webber has been promoted to Chief Executive Officer, and Peter Spadaro has been appointed as the President and Chief Commercial Officer (CCO). Don Webber joined SynCardia in 2018 as […]
BioCardia Reports 2018 Financial Results and Recent Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Commission, and shared recent business highlights. Recent Business […]



